Big Biotechs Gilead Sciences and Biogen may both need to make acquisitions soon. But Vertex Pharmaceuticals is determined not to be one of their targets.
Vertex had a pretty good idea that drug pricing critics wouldn't be so keen on its $259,000-per-year tag for cystic fibrosis med Orkambi. And sure enough, less than three weeks after the combo med won the FDA's green light, the pushback is here.
Vertex Pharmaceuticals' long-awaited cystic fibrosis approval is here--and the combo med Orkambi is just as pricey as analysts expected.
U.S. payers are striking out at drug spending again, highlighting the cost to taxpayers. According to a commissioned report, 10 hot new "breakthrough" meds are expected to cost publicly funded healthcare plans more than $50 billion over the next decade.
HBO premiered an award-winning short documentary about Huntington's disease, a rare, hereditary neurological malady, on Monday night. The film follows actress and filmmaker Marianne Palka as she finds out the results of her genetic test. If someone has a parent with the disease as she did, they have a 50/50 chance of getting the disease. The missing voice? Pharma.
Vertex Pharmaceuticals wants to expand its cystic fibrosis market tenfold, and on Tuesday, it got one step closer. An FDA advisory committee voted 12 to 1 in favor of a new combo drug Orkambi, which marries current CF star Kalydeco with an experimental med, lumacaftor.
Vertex is looking to expand its market for cystic fibrosis drug Kalydeco tenfold, but to do that, it needs the FDA's backing. On Tuesday, it got one step closer, grabbing an advisory committee nod for a new Kalydeco combo.
As an FDA review nears for Vertex's Kalydeco-lumacaftor tandem--approval of which could help Kalydeco reach 10 times the number of cystic fibrosis patients it currently does--the agency's staffers have some concerns.
While pharma's been riding its deal wave, Gilead's been off on its own, coasting on new revenue from blockbuster hep C launches Sovaldi and Harvoni. But one analysts thinks the time is ripe for it to get in on the M&A action--and he's tabbed Vertex as a prime target.
Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex will stir the pot when its new cystic fibrosis combo--expected to win FDA approval later this year--hits the market. But just how much will payers need to shell out for the new med over time? Prime Therapeutics has some ideas.